Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Dr Lal Pathlabs Ltd

| Consolidated Financial Results (Unaudited/Audited) for the Quarter and Year Ended March 31, 2026

Report Source

⬤30th Apr 26

Summary : Dr. Lal PathLabs reports strong FY26 results, expands strategically with acquisitions and new subsidiary, and maintains consistent dividend payouts.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Total expenses: INR 5,666 million (Q4 FY26), INR 21,650 million (FY26).
  2. Standalone Total expenses: INR 5,423 million (Q4 FY26), INR 20,700 million (FY26).
  3. Consolidated Revenue from operations: INR 7,027 million (Q4 FY26), INR 27,629 million (FY26).
  4. Standalone Revenue from operations: INR 6,752 million (Q4 FY26), INR 26,476 million (FY26).
  5. Consolidated Net cash generated from operating activities: INR 6,357 million (FY26) vs INR 5,688 million (FY25).
  6. Consolidated Net cash used in investing activities: INR (4,219) million (FY26) vs INR (3,031) million (FY25).
  7. Consolidated Net cash used in financing activities: INR (2,536) million (FY26) vs INR (3,340) million (FY25).
  8. Standalone Net cash generated from operating activities: INR 6,059 million (FY26) vs INR 5,400 million (FY25).
  9. Standalone Net cash used in investing activities: INR (3,821) million (FY26) vs INR (2,930) million (FY25).
  10. Standalone Net cash used in financing activities: INR (2,560) million (FY26) vs INR (3,248) million (FY25).
  11. Consolidated Total Assets: INR 31,460 million (FY26) vs INR 27,168 million (FY25).
  12. Consolidated Total Equity: INR 25,413 million (FY26) vs INR 22,065 million (FY25).
  13. Standalone Total Assets: INR 30,492 million (FY26) vs INR 26,210 million (FY25).
  14. Standalone Total Equity: INR 24,729 million (FY26) vs INR 21,342 million (FY25).
  15. Acquisition of SDCPL is not a related party transaction.
  16. Both standalone and consolidated financial results are presented and audited.

Corporate Overview

  1. India
  2. Dubai, United Arab Emirates (planned subsidiary)
  3. Nepal (subsidiary)
  4. Bangladesh (subsidiary)
  5. Diagnostic services provider
  6. Laboratory services in India and Asia
  7. Formal and factual, reporting board decisions and financial outcomes.
  8. Acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) for up to INR 20 Crores.
  9. Incorporation of Dr. Lal PathLabs FZCO in Dubai, UAE, as a wholly-owned subsidiary for strategic investments in diagnostics and allied activities.

Risk Factors

  1. New Labour Codes impact costs.
  2. Intense competition in diagnostics sector.
  3. Regulatory changes in healthcare industry.
  4. Integration challenges for new acquisitions.

Key Drivers

  1. Acquisition strengthens Mumbai market presence.
  2. Dubai expansion for strategic growth.
  3. Strong financial results, increased revenue.
  4. Consistent dividend payout to shareholders.

Auditor’s Report

  1. Unmodified opinion on both Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.

Board Commentary

  1. Re-appointment of Dr. Arvind Lal as Executive Chairman and Whole-Time Director for five years.
  2. Re-appointment of Mr. Rajit Mehta as Non-Executive Independent Director for five years.
  3. Designation of Dr. Reena Nakra as Chief Scientific Officer (SMP).
  4. Designation of Dr. Saloni Khera as Chief Lab Management Officer (SMP).
  5. Recommended final dividend of INR 4/- per equity share for FY26.
  6. Total dividend for FY26, including final, is INR 20.5 per equity share.
  7. Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  8. Impact of new Labour Codes on gratuity and leave liability (INR 301 million exceptional item in FY25).
  9. Acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) for up to INR 20 Crores.
  10. Incorporation of Dr. Lal PathLabs FZCO in Dubai, UAE.
  11. Allotment of 82,750 Equity Shares under Employee Stock Option Plan 2022.

Corporate Governance

  1. Auditors complied with ICAI Code of Ethics.
  2. Re-appointment of Non-Executive Independent Director Mr. Rajit Mehta.
  3. Audit Committee reviewed and approved the results.

Management Discussion & Analysis

Future Strategy

  1. Strengthen presence in Mumbai through SDCPL acquisition.
  2. Strategic investment in diagnostics and allied activities in UAE.
  3. Exploring potential acquisitions, tie-ups, or joint ventures in UAE.